AnyTV News
  • News
    • India
    • Regional
    • World
  • Business
  • Politics
  • Sports
  • Entertainment
  • Technology
    • Mobile
    • Gadgets
    • Internet
  • Automobiles
  •  
    • Lifestyle
    • Health
    • Education
    • Viral News
    • Agriculture
    • Astrology
    • Election
No Result
View All Result
  • Select Language
    • English
    • हिंदी
    • ગુજરાતી
  • Advertise With Us
Follow us on Google News
AnyTV News
  • News
    • India
    • Regional
    • World
  • Business
  • Politics
  • Sports
  • Entertainment
  • Technology
    • Mobile
    • Gadgets
    • Internet
  • Automobiles
  •  
    • Lifestyle
    • Health
    • Education
    • Viral News
    • Agriculture
    • Astrology
    • Election
No Result
View All Result
AnyTV News

Immunil launches affordable CAR T-cell therapy for non-Hodgkin lymphoma in India

by Sandhya Hirani
January 20, 2025
Immunil launches affordable CAR T-cell therapy for non-Hodgkin lymphoma in India

New Delhi, January 20 (IANS). Bengaluru-based cell and gene therapy startup Immunil Therapeutics on Monday launched the country’s first personalized and precise CAR T-cell therapy, named ‘Quartemi’. This therapy is for B-cell non-Hodgkin lymphoma (B-NHL) in adults.

B-cell non-Hodgkin lymphoma is a type of blood cancer that affects B-cells in the body’s lymphatic system. About 80-85% of non-Hodgkin lymphoma cases in India are of this type.

‘Quartemi’ which has received approval from the Indian drug regulator CDSCO. This is an individualized therapy for adult patients whose cancer has come back frequently or who has not responded to other treatments, such as chemotherapy. It is also licensed by Hospital Clínic de Barcelona (HCB), Spain, a globally renowned institution at the forefront of cell therapy innovation.

This therapy modifies the patient’s immune cells and prepares them to destroy cancer cells. This technology developed in Bengaluru has the potential to provide long-term relief to patients.

According to the company, the price of Quartemi is ten times lower than a similar product available in the US. Kiran Mazumdar-Shaw, co-founder of the company, said, “Our goal is to make cancer treatment affordable and accessible. Through Quartem, we are bringing advanced and personalized treatment to India, based on world-class technology.”

Immunil, launched in 2019, plans to trial India’s first CAR T cell therapy in 2022. The trial took place in PGIMER, Chandigarh, and several hospitals in Bengaluru and Chennai. In this technique, the patient’s T-cells are genetically modified to destroy cancer cells.

According to trials in India and Spain, the safety and effectiveness of Quertemy is similar to that of CAR T-cell therapies approved in the US.

Dr. Siddharth Mukherjee, Co-Founder of Immunil and renowned cancer expert, said, “The launch of Quartemi is a historic step in the fight against cancer in India. Through world-class research and indigenous manufacturing, we are providing new hope to blood cancer patients. Giving.”

–IANS

AS/

SendShareShareTweetSharePinShareSend

Related Posts

ADHD symptoms, autistic symptoms and anxiety affect genetic factor: study
Health

ADHD symptoms, autistic symptoms and anxiety affect genetic factor: study

by Sandhya Hirani
June 10, 2025
भारत की जनसंख्या 1.46 अरब तक पहुंची, प्रजनन दर में गिरावट : यूएनएफपीए
Health

India’s population reaches 1.46 billion, declining fertility rate: UNFPA

by Sandhya Hirani
June 10, 2025
कड़वे-कड़वे मेथी दाने में छिपी है मिठास, जानते हैं कैसे?
Health

Sweetness is hidden in bitter fenugreek seeds, know how?

by Sandhya Hirani
June 10, 2025
AnyTV News

AnyTVNews is a prominent digital news channel in India, known for delivering the latest updates on politics, sports, entertainment, and local events. The channel’s dedicated team of journalists and reporters ensures that viewers receive accurate and timely information from every corner of country. AnyTVNews has built a reputation for its fast and reliable news service, making it a trusted source for the people of India. The channel’s programs and news bulletins are highly popular among viewers, establishing AnyTVNews as a significant player in the news landscape.

CONNECT WITH US

TRENDING TOPICS

  • Agriculture
  • Astrology
  • Automobiles
  • Business
  • DIY
  • Education
  • Election
  • Entertainment
  • Gadgets
  • Health
  • India
  • Internet
  • Lifestyle
  • Mobile
  • News
  • Opinion
  • Politics
  • Regional
  • Sports
  • Technology
  • Uncategorized
  • Viral News
  • World

READ NEWS IN

  • Hindi
  • Gujarati
  • English

FOLLOW US ON

Follow us on Google News
  • About Us
  • Advertise With Us
  • Disclaimer
  • DMCA Policy
  • Privacy Policy
  • Contact Us

© 2024 AnyTV News Network All Rights Reserved.

No Result
View All Result
  • Select Language
    • हिंदी
    • ગુજરાતી
  • News
    • India
    • Regional
    • World
  • Business
  • Politics
  • Sports
  • Entertainment
  • Technology
    • Mobile
    • Gadgets
    • Internet
  • Lifestyle
  • Health
  • Automobiles
  • Education
  • Viral News
  • Agriculture
  • Astrology
  • Election
Follow us on Google News

© 2024 AnyTV News Network All Rights Reserved.